Rebooting cytokines

To degrade or not to degrade? That is the question for some receptor agonist drugs. Drug design usually focuses on the ability of a protein to bind to a receptor, but in some instances reducing receptor binding affinity is the goal.

Some ligand-receptor complexes on the

Read the full 460 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE